FDA WARNING_LETTER - GyNova LLC - November 05, 2007

On January 31, 2008, the FDA issued a Warning Letter to GyNova LLC, following an inspection from June to November 2007. The inspection determined that GyNova LLC, a Specification Developer and Distributor of the G*SPEC Weighted Articulated Vaginal Speculum, was operating in violation of the Quality System (QS) regulation (21 CFR Part 820). The devices were deemed adulterated under section 501(h) of the Act due to non-conformity with Current Good Manufacturing Practice (CGMP) requirements.

Key violations included: 1. **Failure to establish design control procedures (21 CFR 820.30(a)):** Two device modifications were implemented without documented rationale or approval, despite being made due to complaints about the device catching on sutures, slipping, and needing increased handle strength. 2. **Failure to document process validation activities (21 CFR 820.75(a)):** There was no documentation evaluating the effect of an increased radiation dose on pouch seals or the product itself, despite a contracted sterilizer providing certificates of processing. 3. **Lack of complaint handling procedures (21 CFR 820.198):** The firm had no procedures for receiving, reviewing, or evaluating complaints, nor did it maintain a record of complaints. 4. **Inadequate personnel training (21 CFR